Acute Coronary Syndrome

Type: Keyphrase
Name: Acute Coronary Syndrome
First reported 18 hours ago - Updated 9 hours ago - 1 reports

AstraZeneca study shows flexibility of Brilinta treatment approach

:08 in Pharmaceutical Company Product News AstraZeneca has reported data from a new phase IV trial that further underlines the benefits of its acute coronary syndrome therapy Brilinta. Results from the Atlantic study has indicated that the drug offers ... [Published Zenopa - 18 hours ago]
First reported 11 hours ago - Updated 11 hours ago - 1 reports

Biodegradable stent matches gold standard for safety, efficacy

A next-generation biodegradable drug-eluting stent proved noninferior to the standard of care in a randomized clinical trial that imposed minimal exclusion criteria, according to results published online Sept. 1 in The Lancet and simultaneously presented ... [Published Cardiovascular Business - 11 hours ago]
First reported 13 hours ago - Updated 13 hours ago - 1 reports

Ask the Doc: Don't discount the love drug

A 91-year-old patient of mine recently received a very powerful drug. The effect was remarkable. He looks and feels almost 20 years younger.This is the same patient I admitted as the very first admission to the new hospital in Sevierville on Sunday, Feb. ... [Published Mountain Press - 13 hours ago]
Entities: Drugs, dyspnea, Heart Attack
First reported 20 hours ago - Updated 20 hours ago - 1 reports

FFR-Guided PCI — FAME May Not Be So Fleeting after All

Treatment strategies for patients with stable coronary artery disease are driven by the principles of reducing symptoms of coronary insufficiency, preventing myocardial infarction, and prolonging survival. Although percutaneous coronary intervention (PCI) ... [Published DailyMe.Com - 20 hours ago]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

Inhibiting inflammatory enzyme after heart attack does not reduce risk of subsequent event -- ScienceDaily

In patients who experienced an acute coronary syndrome (ACS) event (such as heart attack or unstable angina), use of the drug darapladib to inhibit the enzyme lipoprotein-associated phospholipase A2 (believed to play a role in the development of atherosclerosis) ... [Published DailyMe.Com - Sep 02 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Diabetes Mellitus and Clopidogrel Response Variability ∗

Platelet P2Y 12 -receptor antagonists reduce major adverse cardiovascular events after percutaneous coronary intervention (PCI) and in acute coronary syndrome (ACS) ( 1 – 4 ). Together with aspirin, they are the cornerstones of adjunctive medical therapy ... [Published Journal of the American College of Cardiology - Sep 01 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Coronary Artery Manifestations of Fibromuscular Dysplasia

Fibromuscular dysplasia (FMD) involving the coronary arteries is an uncommon but important condition that can present as acute coronary syndrome, left ventricular dysfunction, or potentially sudden cardiac death. Although the classic angiographic “string ... [Published Journal of the American College of Cardiology - Sep 01 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Astra heart pill safe to use in ambulance but no extra benefit

(Reuters) - AstraZeneca'sblood-thinning drug Brilinta is safe to use in the ambulancewhen heart attack patients are being rushed to hospital butgiving it early in this way does not provide any extra benefit.That is the conclusion of a clinical study presented ... [Published Reuters - Sep 01 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Women at greater stroke risk from resistant hypertension

Resistant hypertension increases the risk of stroke by 35 per cent in women and 20 per cent in elderly patients, according to new research.The findings presented at the European Society of Cardiology (ESC) Congress in Barcelona by Dr Kuo-Yang Wang from ... [Published Business Standard India - Sep 01 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Bayer HealthCare launches three new studies of Xarelto

:24 in Pharmaceutical Company Product News Bayer HealthCare has announced a new expansion of the global clinical development programme for Xarelto, its rivaroxaban-based oral Factor Xa inhibitor therapy. The three new studies will assess the safety and ... [Published Zenopa - Sep 01 2014]
First reported Aug 31 2014 - Updated Sep 01 2014 - 2 reports

Resistant hypertension increases stroke risk by 35% in women and 20% in elderly Taiwanese

: Resistant hypertension increases the risk of stroke by 35% in women and 20% in elderly Taiwanese patients, according to research presented at ESC Congress today by Dr Kuo-Yang Wang from Taiwan. The findings suggest that gender and age should be added ... [Published European Society of Cardiology - Aug 31 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 2 reports

Bayer Aims to Expand Xarelto Use Despite Known Risks, Rottenstein Law Group LLP Notes with Concern

Rockville Centre, NY -- (SBWIRE) -- 08/29/2014 -- According to a Reuters report, Xarelto manufacturer Bayer is going to be testing the drug—currently very popular as a treatment for preventing strokes—on patients with “embolic stroke of undetermined source ... [Published Reliance Trust - Aug 29 2014]

Quotes

...Jude's CMO, told Medical Device Daily, via e-mail. "We now know that after two years, the benefits of FFR-guided PCI were sustained and that patients who underwent FFR-guided PCI saw reduced rates of death, myocardial infarctions and urgent revascularizations."
...AF trial," said Anne Hermanowski Vosatka, M D , Ph D,  F A C C , Vice President and Compound Development Team Leader for rivaroxaban,  Janssen. "Xarelto is the most studied and widely prescribed Factor Xa inhibitor in the  world today. We remain committed to continuing to advance our understanding of how  this medicine can address critical medical needs. Beyond X-VeRT, we have initiated 10  additional studies in high-risk patient populations, including acute coronary syndrome,  embolic stroke of undetermined source, and peripheral artery disease."
"Use of a CT angiography–guided strategy to investigate patients with low to intermediate risk of ACS who present to the ED with chest pain is safe at long-term follow-up" the authors concluded
"The proximal segments of non–infarct-related arteries in STEMI patients feature a high atherosclerotic plaque burden, with a majority of lesions"

More Content

All (264) | News (222) | Reports (0) | Blogs (37) | Audio/Video (0) | Fact Sheets (2) | Press Releases (2)
sort by: Date | Relevance
European Society of Cardiology 2014: St Jude's ... [Published Medical Device Daily - 3 hours ago]
Rivaroxaban May Be Alternative to Vitamin K Ant... [Published Diagnostic & Invasive Cardiology - 7 hours ago]
AstraZeneca Reports Data on Brilinta from ATLAN... [Published Zacks.com - 9 hours ago]
Bayer/Johnson & Johnson to Expand Xarelto Label... [Published Zacks.com - 10 hours ago]
Biodegradable stent matches gold standard for s... [Published Cardiovascular Business - 11 hours ago]
New NICE guidance published [Published British Journal of Cardiology - 12 hours ago]
Towards personalised medicine: HEART UK 28th An... [Published British Journal of Cardiology - 12 hours ago]
Ask the Doc: Don't discount the love drug [Published Mountain Press - 13 hours ago]
St. Jude Medical's Tech Helps Coronary Artery P... [Published Zacks.com - 14 hours ago]
Emergency CT angiography can slash unnecessary ... [Published FierceMedicalImaging - 15 hours ago]
Fractional Flow Reserve Gains Support in Stable... [Published Forbes.com - 16 hours ago]
Rosuvastatin Reduces Plaque Volume in STEMI Pat... [Published Diabetes Care - 17 hours ago]
Capstone Therapeutics Announces Phase 1a Result... [Published WGNT - 18 hours ago]
AstraZeneca study shows flexibility of Brilinta... [Published Zenopa - 18 hours ago]
New clinical trial results demonstrate importan... [Published Medical Devices Business Review - 19 hours ago]
FFR-Guided PCI — FAME May Not Be So Fleeting af... [Published DailyMe.Com - 20 hours ago]
FFR-Guided PCI — FAME May Not Be So Fleeting af... [Published New England Journal of Medicine - 23 hours ago]
Inhibiting inflammatory enzyme after heart atta... [Published DailyMe.Com - Sep 02 2014]
Reperfusion Therapy for ST Elevation Acute Myoc... [Published Theheart.org - Sep 02 2014]
New Clinical Trial Results Demonstrate Importan... [Published Investor's Business Daily - Sep 01 2014]
Coronary Artery Manifestations of Fibromuscular... [Published Journal of the American College of Cardiology - Sep 01 2014]
Diabetes Mellitus and Clopidogrel Response Vari... [Published Journal of the American College of Cardiology - Sep 01 2014]
Women at greater stroke risk from resistant hyp... [Published Business Standard India - Sep 01 2014]
Bayer HealthCare launches three new studies of ... [Published Zenopa - Sep 01 2014]
Prehospital Ticagrelor in ST-Segment Elevation ... [Published New England Journal of Medicine - Sep 01 2014]
New data indicates Brilinta/Brilique™ has the f... [Published Noodls - Sep 01 2014]
Astra heart pill safe to use in ambulance but n... [Published Reuters - Sep 01 2014]
Bayer to Launch Three New Xarelto Trials [Published PharmaAsia - Aug 31 2014]
New studies planned to further expand indicatio... [Published Pharma Letter - Aug 31 2014]
Huge Decreases in LDL Cholesterol With Alirocum... [Published American Journal of Public Health - Aug 31 2014]
1 2 3 4 5 6 7 8 9
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
ESC: Darapladib Fails in ACS Trial (CME/CE) [Published MedPageToday.com - medical news plus CME for ph ... - Aug 31 2014]
BARCELONA (MedPage Today) -- Inhibiting an enzyme involved in inflammation has once again failed to reduce cardiovascular events, this time in patients who had been hospitalized with an acute coronary syndrome event, researchers reported here. ...
Top stories in health and medicine, August 20, ... [Published KevinMD.com - Aug 20 2014]
From  MedPage Today : Moving Target for BP Guidelines . The current blood pressure target recommendations may need to be revisited in hypertensive patients with coronary artery disease who are 60 years and older. Transcatheter Mitral Valve Repair ...
ACS and Stroke Hospitalizations Decline (CME/CE) [Published MedPageToday.com - medical news plus CME for ph ... - Aug 19 2014]
(MedPage Today) -- Hospitalizations, readmission rates, and mortality outcomes have declined for patients with acute coronary syndrome and stroke from 1999 to 2011, researchers reported. ...
Top stories in health and medicine, August 13, ... [Published KevinMD.com - Aug 13 2014]
From  MedPage Today : CT Images Can Inform Clinical Decisions . The identification of high-risk plaque features using noninvasive CT imaging is a useful and independent predictor of acute coronary syndrome (ACS) in patients presenting to emergency ...
ACS: CT Images Can Inform Clinical Decisions (C... [Published MedPageToday.com - medical news plus CME for ph ... - Aug 12 2014]
(MedPage Today) -- The identification of high-risk plaque features using noninvasive CT imaging is a useful and independent predictor of acute coronary syndrome in patients presenting to emergency departments with acute chest pain, researchers report ...
1 2 3 4 5 6 7 8

Press Releases

sort by: Date | Relevance
Regado Biosciences Announces $20 Million Privat... [Published PR Newswire - Jan 31 2014]
The Acute Coronary Syndrome 12-Month Posthospit... [Published PR Newswire - Dec 11 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.